Nanobiotix S.A., a clinical-stage biotech company, announced its voting rights and share capital details as of October 31, 2026. The company has 50,968,893 shares outstanding with a total of 54,726,179 theoretical voting rights and 54,704,061 exercisable voting rights. This update complies with French financial regulations and informs shareholders about the current voting power structure. Nanobiotix continues its development in nanotechnology-based therapies, with operations in France and the US, and remains listed on Euronext Paris and Nasdaq.
Nanobiotix S.A.'s voting rights and share capital details as of October 31, 2026, provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 13, 2026 04:11 WIB: out of 150 priced US health stocks, 23 rose and 124 fell. Notable movers include CTXR at USD 0.53 with an 11.19% increase and a typical hold time of 19 days, SMMT at USD 15.10 down 9.25%, and IBRX at USD 6.06 down 9.15%, with CTXR showing 84% sell activity on Pluang.
Super League Enterprise, a company specializing in audience intelligence and media activation for the gaming industry, announced it will release its financial results for the third quarter ending September 30, 2026, on November 16, 2026, after market...
Stantec Inc. reported a 9.4% increase in net revenue to $1.9 billion for Q3 2026, driven by organic and acquisition growth. Adjusted EBITDA rose 16.6% to $377.1 million with a record margin of 20.2%, while adjusted EPS grew 23.5% to $1.89. The compan...
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
